MADELINE LEWIS: Open Payments
NPI 1467161505 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,907 in 112 payments from 16 companies in 2025. Trend: 2023 $1,059 · 2024 $1,338 · 2025 $1,907
Food & beverage: $1,907
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $599 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $313 |
| Madrigal Pharmaceuticals | 10 | $203 |
| Regeneron Healthcare Solutions, Inc. | 8 | $143 |
| GlaxoSmithKline, LLC. | 1 | $95 |
| Ipsen Biopharmaceuticals, Inc | 3 | $79 |
| Ardelyx, Inc. | 4 | $79 |
| GENZYME CORPORATION | 4 | $76 |
| Aimmune Therapeutics, Inc. | 4 | $74 |
| Janssen Biotech, Inc. | 3 | $72 |
Products named: RINVOQ, ENTYVIO, DUPIXENT, REZDIFFRA, SKYRIZI, EOHILIA, IBSRELA, ZENPEP.
Industry payments across ID — which companies pay providers there.
